Vertex Pharmaceuticals
VRTX
482 hedge funds and large institutions have $20.7B invested in Vertex Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 204 increasing their positions, 162 reducing their positions, and 61 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 204 | Existing positions reduced: 162
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
10% more capital invested
Capital invested by funds: $18.7B → $20.7B (+$1.96B)
1% more call options, than puts
Call options by funds: $81.8M | Put options by funds: $81.3M
4% less funds holding
Funds holding: 502 → 482 (-20)
23% less first-time investments, than exits
New positions opened: 47 | Existing positions closed: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$613M |
| 2 |
Jennison Associates
New York
|
+$166M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$61.3M |
| 4 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
+$50.6M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$45.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
-$399M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$152M |
| 3 |
Two Sigma Investments
New York
|
-$86M |
| 4 |
Goldman Sachs
New York
|
-$66.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$66.7M |
VRTX Hedge Fund Activity: Q2 2016 in Review
482 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2016, worth a combined $20.7B — up 10% from $18.7B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of VRTX and 47 opened new positions — a net loss of 14 holders — while 162 trimmed existing stakes and 204 added.
The largest buyer was Fidelity Investments, adding an estimated $613M. The largest seller was Royal London Asset Management, cutting an estimated $399M.
- 482 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2016, down from 502 in Q1 2016.
- Funds reported $20.7B of Vertex Pharmaceuticals stock for Q2 2016, up 10% quarter-over-quarter.
- 47 funds opened new Vertex Pharmaceuticals positions in Q2 2016 and 61 closed out, a net change of -14 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2016 was Fidelity Investments, an estimated $613M added.
- The largest Vertex Pharmaceuticals seller in Q2 2016 was Royal London Asset Management, an estimated $399M sold.
Based on aggregated 13F filings for Q2 2016.